VALIANT LABORATORIES
|
VALIANT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|
| Operational & Financial Ratios | |||
| Earnings Per Share (Rs) | -0.51 | 0.07 | 8.91 |
| CEPS(Rs) | -0.02 | 0.49 | 8.71 |
| DPS(Rs) | - | - | - |
| Book NAV/Share(Rs) | 53.93 | 54.51 | 30.86 |
| Tax Rate(%) | -45.52 | 141.53 | 23.96 |
| Margin Ratios | |||
| Core EBITDA Margin(%) | -3.52 | -4.62 | 10.50 |
| EBIT Margin(%) | -1.00 | -0.38 | 11.50 |
| Pre Tax Margin(%) | -1.13 | -0.42 | 11.42 |
| PAT Margin (%) | -1.65 | 0.18 | 8.68 |
| Cash Profit Margin (%) | -0.08 | 1.26 | 9.15 |
| Performance Ratios | |||
| ROA(%) | -0.59 | 0.12 | 13.62 |
| ROE(%) | -0.93 | 0.19 | 28.86 |
| ROCE(%) | -0.40 | -0.29 | 24.01 |
| Asset Turnover(x) | 0.36 | 0.66 | 1.57 |
| Sales/Fixed Asset(x) | 1.89 | 2.67 | 5.04 |
| Working Capital/Sales(x) | 1.00 | 0.93 | 3.34 |
| Efficiency Ratios | |||
| Fixed Capital/Sales(x) | 0.53 | 0.37 | 0.20 |
| Receivable days | 161.25 | 134.62 | 96.82 |
| Inventory Days | 19.16 | 23.11 | 14.26 |
| Payable days | 104.79 | 79.77 | 62.43 |
| Valuation Parameters | |||
| PER(x) | - | 1,837.23 | - |
| PCE(x) | -3,072.31 | 276.81 | - |
| Price/Book(x) | 1.42 | 2.67 | - |
| Yield(%) | - | - | - |
| EV/Net Sales(x) | 2.84 | 3.31 | 0.27 |
| EV/Core EBITDA(x) | 501.61 | 472.86 | 2.27 |
| EV/EBIT(x) | -283.31 | -871.00 | 2.36 |
| EV/CE(x) | 1.07 | 1.93 | 0.57 |
| M Cap / Sales | 2.50 | 3.47 | - |
| Growth Ratio | |||
| Net Sales Growth(%) | -26.74 | -45.48 | - |
| Core EBITDA Growth(%) | -40.72 | -96.81 | - |
| EBIT Growth(%) | -93.34 | -101.80 | - |
| PAT Growth(%) | -788.74 | -98.90 | - |
| EPS Growth(%) | -788.74 | -99.17 | - |
| Financial Stability Ratios | |||
| Total Debt/Equity(x) | 0.52 | 0.32 | 0.59 |
| Current Ratio(x) | 3.23 | 7.76 | 2.97 |
| Quick Ratio(x) | 3.16 | 7.41 | 2.71 |
| Interest Cover(x) | -7.63 | -8.89 | 151.32 |
| Total Debt/Mcap(x) | 0.36 | 0.12 | - |
Compare Financial Ratios of peers of VALIANT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| VALIANT LABORATORIES | ₹368.7 Cr | 0.9% | -8.6% | -31% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,794.0 Cr | 1.7% | -2.3% | 8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,956.0 Cr | 2% | -2.2% | 1.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,820.0 Cr | -1.8% | -0.1% | 36.7% | Stock Analytics | |
| CIPLA | ₹109,370.0 Cr | -2% | -3.3% | -9.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,133.0 Cr | -0.6% | -3.8% | -6.9% | Stock Analytics | |
VALIANT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| VALIANT LABORATORIES | 0.9% |
-8.6% |
-31% |
| SENSEX | 1.7% |
2.1% |
-6% |
You may also like the below Video Courses
